Talaromyces marneffei

The species was first isolated in 1956 from a bamboo rat (Rhizomys sinensis) in Vietnam by G. Segretain, who named it Penicillium marneffei in honor of Marneffe, a French physician. Molecular phylogenetic analyses placed it within the genus Talaromyces, leading to its reclassification as Talaromyces marneffei in 2011.¹ The species is the only known thermally dimorphic member of the genus, a trait that is central to its pathogenicity.

The fungus is found in soil and is associated with bamboo rats, which are natural reservoirs. Human infection is acquired by inhalation of conidia from the environment, not from animal contact. The exact ecological niche remains poorly defined, but the geographic distribution correlates with regions of high humidity and rainfall. In endemic areas, talaromycosis is a common AIDS-defining illness, with incidence peaking during the rainy season.²

Infection typically presents with fever, weight loss, skin lesions (often molluscum-like), hepatosplenomegaly, and respiratory symptoms. Disseminated disease is common in HIV patients with CD4 counts below 100 cells/μL.³ Diagnosis is confirmed by culture from blood, bone marrow, skin biopsy, or other sterile sites; histopathology shows yeast cells with characteristic central septation. Rapid antigen tests and PCR are increasingly used for early detection.

First-line therapy is intravenous amphotericin B, followed by oral itraconazole for consolidation and secondary prophylaxis.⁴ Voriconazole is an alternative, but itraconazole remains the mainstay for maintenance. In HIV patients, antiretroviral therapy is essential to restore immunity. There is no vaccine; prevention relies on avoiding exposure in endemic areas and prophylactic itraconazole in high-risk patients.

Beyond HIV, talaromycosis has been reported in patients with other immunodeficiencies, including those on immunosuppressive therapy or with hematological malignancies. The fungus can also infect immunocompetent individuals, though rarely. A notable case involved a laboratory-acquired infection, highlighting its potential as a biosafety concern. The yeast form is unique among Talaromyces species, and its ability to survive inside macrophages is a key virulence factor. Recent genomic studies have identified specific genes involved in thermoregulation and host adaptation, offering potential targets for novel therapies.¹

Thermally dimorphic

Capable of existing in two different morphological forms depending on temperature.

Conidia

Asexual spores produced by fungi.

CD4 count

A measure of immune function; low counts indicate advanced HIV infection.

Secondary prophylaxis

Long-term treatment to prevent recurrence of an infection.